Navigation Links
BYDUREON (TM) FDA Review Timeline Set with PDUFA Action Date of October 22, 2010
Date:5/6/2010

SAN DIEGO, INDIANAPOLIS and WALTHAM, Mass., May 6, 2010 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN), Eli Lilly and Company (NYSE: LLY) and Alkermes, Inc. (Nasdaq: ALKS) today announced that the U.S. Food and Drug Administration (FDA) has classified the BYDUREON™ (exenatide for extended-release injectable suspension) complete response as a Class 2 resubmission and assigned a new Prescription Drug User Fee Act (PDUFA) action date of October 22, 2010.

"If approved, BYDUREON will be the first once-weekly treatment for type 2 diabetes, and we are committed to making this important therapeutic option available to patients as soon as possible," said Orville G. Kolterman, M.D., senior vice president of research and development, Amylin Pharmaceuticals. "We will continue to work closely with the agency through this final stage of the review process."

The new drug application (NDA) for BYDUREON was submitted in May 2009 and was based on data from the DURATION clinical trial program, as well as more than seven years of clinical experience with BYETTA® (exenatide) injection. The agency issued a complete response letter to the companies in March 2010 and the companies responded to that letter in April 2010.

BYDUREON (pronounced by-DUR-
'/>"/>

SOURCE Amylin Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. DJO Incorporateds Pending Merger With ReAble Therapeutics Clears U.S. Antitrust Review
2. Thoratec Announces HeartMate II(R) PMA Will be Reviewed by FDA Advisory Panel
3. Amyris Biotechnologies Co-Founder Neil Renninger Named to Technology Reviews Prestigious TR35 List of Top Young Innovators
4. Arena Pharmaceuticals Continues Phase 3 BLOOM Obesity Trial Following Independent Echocardiogaphic Data Safety Monitoring Board Review
5. Arena Pharmaceuticals Continues Phase 3 BLOOM Obesity Trial Following Independent Echocardiographic Data Safety Monitoring Board Review
6. AEterna Zentaris Announces Outcome of Managements Strategic Review
7. Thomson Scientific Publishes Who Is Making The Biggest Splash? - A Quarterly Review of Scientific Literature on Drugs and Therapies From April - June 2007
8. BioMS Medicals relapsing-remitting multiple sclerosis trial receives positive review from Data Safety Monitoring Board
9. Neurobiological Technologies, Inc. (Nasdaq: NTII) Q1/08 Review Issued By Scimitar Equity Research, Inc.
10. BioMS Medicals phase III U.S. multiple sclerosis trial receives positive safety review from Data Safety Monitoring Board
11. BioMS Medicals pivotal international multiple sclerosis trial receives positive review from Data Safety Monitoring Board
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... ... July 30, 2015 , ... ... a field clinical study of its canine osteoarthritis stem cell product, currently under ... (Kansas City, KS) and will be marketed in the US by Aratana. This ...
(Date:7/30/2015)... HIGHLIGHTS:Q2 2015 Results (all changes ... Reported sales were $697 million compared to $701 million ... by 8%, and changes in foreign currency exchange rates ... 1%. , By business unit, organic sales growth ... in SAFC Commercial. , Reported diluted EPS was ...
(Date:7/29/2015)... Sanofi, un leader mondial ... pour le premier semestre 2015. Le Directeur Général ... Visionner l,interview vidéo et lire la transcription ... Au sommaire de l,interview :  - ... - Diabète - Praluent ...
(Date:7/29/2015)... Ala., July 29, 2015  HealthSouth ... nation,s largest providers of post-acute healthcare services, offering ... its results of operations for the second quarter ... quarter was characterized by strong volume growth in ... Adjusted EBITDA," said Jay Grinney, President and Chief ...
Breaking Biology Technology:VetStem Biopharma Successfully Completes Large Milestone Efficacy Study for its Flagship Canine Osteoarthritis Stem Cell Product 2VetStem Biopharma Successfully Completes Large Milestone Efficacy Study for its Flagship Canine Osteoarthritis Stem Cell Product 3Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 2Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 3Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 4Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 5Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 6Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 7Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 8Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 9Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 10Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 11Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 12Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 13Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 14Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 15Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 16Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 17Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 18Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 19Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 20HealthSouth Reports Results for Second Quarter 2015 2HealthSouth Reports Results for Second Quarter 2015 3HealthSouth Reports Results for Second Quarter 2015 4HealthSouth Reports Results for Second Quarter 2015 5HealthSouth Reports Results for Second Quarter 2015 6HealthSouth Reports Results for Second Quarter 2015 7HealthSouth Reports Results for Second Quarter 2015 8HealthSouth Reports Results for Second Quarter 2015 9HealthSouth Reports Results for Second Quarter 2015 10HealthSouth Reports Results for Second Quarter 2015 11HealthSouth Reports Results for Second Quarter 2015 12HealthSouth Reports Results for Second Quarter 2015 13HealthSouth Reports Results for Second Quarter 2015 14HealthSouth Reports Results for Second Quarter 2015 15
... MEDX ) announced today that it is scheduled ... at 1:25 p.m. Eastern Time on,Tuesday, June 10, 2008. ... in the Investor Relations section of the Medarex website ... will be available,following the event., About Medarex, ...
... Patents Continue to be Granted Globally, ... (OTC,Bulletin Board: SKVI) (Website: http://www.skinvisible.com ), ... that enhances topically applied,products, has been granted ... provides protection in the areas of "Topical ...
... SAN DIEGO, June 2 Amylin Pharmaceuticals,Inc. (Nasdaq: ... will present new data,for its FDA-approved diabetes drugs, ... its pipeline diabetes and,obesity drug candidates at the ... held in San Francisco, CA from June 6 ...
Cached Biology Technology:Medarex to Present at the 29th Annual Goldman Sachs Healthcare Conference 2Skinvisible Patent Granted in Australia 2Skinvisible Patent Granted in Australia 3Amylin Pharmaceuticals to Present Promising Data From Diabetes and Obesity Programs at ADA 2008 2Amylin Pharmaceuticals to Present Promising Data From Diabetes and Obesity Programs at ADA 2008 3Amylin Pharmaceuticals to Present Promising Data From Diabetes and Obesity Programs at ADA 2008 4Amylin Pharmaceuticals to Present Promising Data From Diabetes and Obesity Programs at ADA 2008 5Amylin Pharmaceuticals to Present Promising Data From Diabetes and Obesity Programs at ADA 2008 6Amylin Pharmaceuticals to Present Promising Data From Diabetes and Obesity Programs at ADA 2008 7
(Date:7/8/2015)... YORK , July 8, 2015  BD (Becton, ... BD & Guidepoint Mentor, a new program ... Guidepoint,s expert network services. BD is ... to improve healthcare delivery and outcomes and, with the ... entrepreneur will be able to directly engage with industry ...
(Date:7/8/2015)... CORAL SPRINGS, Florida , July 8, 2015 ... is constantly evolving as this summer,s must have products such ... high in demand as popularity for biometrics based devices continues ... today are NXT-ID, Inc. (NASDAQ: NXTD ), Google Inc. ... Fitbit Inc. (NYSE: FIT ), GoPro, Inc. (NASDAQ: ...
(Date:7/7/2015)... Calif. , July 7, 2015  Based ... market, Frost & Sullivan recognizes Credence ID, LLC ... Entrepreneurial Company of the Year Award. Credence ... to aid in its mission of offering enrollment ... populations globally. As Credence ID was formed by ...
Breaking Biology News(10 mins):BD and Guidepoint Team to Connect Healthcare Start-up Companies With Business and Scientific Experts 2BD and Guidepoint Team to Connect Healthcare Start-up Companies With Business and Scientific Experts 3Consumers Flock to This Summer's Must Have Tech Gadgets as Latest Digital Wallets, Smart Technology & Wearable Products Continue to Grow in Popularity & Functionality 2Consumers Flock to This Summer's Must Have Tech Gadgets as Latest Digital Wallets, Smart Technology & Wearable Products Continue to Grow in Popularity & Functionality 3Consumers Flock to This Summer's Must Have Tech Gadgets as Latest Digital Wallets, Smart Technology & Wearable Products Continue to Grow in Popularity & Functionality 4Consumers Flock to This Summer's Must Have Tech Gadgets as Latest Digital Wallets, Smart Technology & Wearable Products Continue to Grow in Popularity & Functionality 5Consumers Flock to This Summer's Must Have Tech Gadgets as Latest Digital Wallets, Smart Technology & Wearable Products Continue to Grow in Popularity & Functionality 6Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 2Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 3Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 4Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 5
... is the latest American Chemical Society (ACS) News Service Weekly ... & Engineering News.,Please credit the individual journal or the American ... CONTENT IS FOR IMMEDIATE USE EXCEPT ARTICLE #5, which is ... ARTICLE #1 FOR IMMEDIATE RELEASE ...
... have been lost from West Antarctica and the Antarctic peninsula ... University of Bristol and published online this week in Nature ... has been roughly stable, with neither loss nor accumulation over ... of Bristol and colleagues estimated the flux of ice from ...
... and a survey across the entire human genome, an ... of Health (NIH) has found evidence that common genetic ... minor role in human height. The findings were released ... Nature Genetics. The variants most strongly associated with ...
Cached Biology News:American Chemical Society's weekly PressPac -- Jan. 9, 2008 2American Chemical Society's weekly PressPac -- Jan. 9, 2008 3American Chemical Society's weekly PressPac -- Jan. 9, 2008 4American Chemical Society's weekly PressPac -- Jan. 9, 2008 5American Chemical Society's weekly PressPac -- Jan. 9, 2008 6American Chemical Society's weekly PressPac -- Jan. 9, 2008 7American Chemical Society's weekly PressPac -- Jan. 9, 2008 8American Chemical Society's weekly PressPac -- Jan. 9, 2008 9Antarctic ice loss 2Researchers uncover new piece to the puzzle of human height 2Researchers uncover new piece to the puzzle of human height 3Researchers uncover new piece to the puzzle of human height 4
... Mouse monoclonal [PRMT5-21] to PRMT5 Arginine ... which has only recently been linked to ... PRMT enzymes have been identified in mammalian ... have essential regulatory functions by methylation of ...
... complete kit contains enough separation ... a total of 5 x ... includes the StemSep red magnet ... and buffers for the specific ...
... Exiqons LNA technology enables sensitive, fast and ... intact chromosomes. Short hybridisation time ... cells and chromosome spreads Multiplex capability ... probes Probes available with ...
... dehydrogenase catalyzes a reversible reaction between ... with NAD as a coenzyme. GPDH ... progenitor cells into adipocytes and, thus, ... been used as an index for ...
Biology Products: